ClinicalTrials.Veeva

Menu

Phase II Trial of RAD001 in Refractory Colorectal Cancer

S

Swedish Medical Center

Status and phase

Completed
Phase 2

Conditions

Colorectal Cancer

Treatments

Drug: RAD001

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00337545
CRAD0012467
Swedish Cancer Institute 05128

Details and patient eligibility

About

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Full description

Study is completed and closed.

Enrollment

22 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
  • Measurable disease
  • ECOG 0-2

Exclusion criteria

  • CNS disease
  • Chemotherapy or radiotherapy < 4 weeks prior
  • Active bleeding diathesis

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems